References
- Robertson JS, Chui WK, Genazzani AA, Malan SF, Lopez de la Rica Manjavacas A, Mignot G, et al. The INN global nomenclature of biological medicines: a continuous challenge. Biologicals 2019;60:15-23. https://doi.org/10.1016/j.biologicals.2019.05.006
- Jerome JB, Sagon P. The USAN nomenclature system. JAMA 1975;232:294-299. https://doi.org/10.1001/jama.1975.03250030048023
- Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008;7:21-39. https://doi.org/10.1038/nrd2399
- Mohammadi E, Seyedhosseini-Ghaheh H, Mahnam K, Jahanian-Najafabadi A, Mir Mohammad Sadeghi H. Reteplase: structure, function, and production. Adv Biomed Res 2019;8:19. https://doi.org/10.4103/abr.abr_169_18
- Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 2003;72:23-31. https://doi.org/10.1086/345309
- Babaesfahani A, Bajaj T. Glatiramer. Treasure Island: StatPearls Publishing, 2020.
- Mayrhofer P, Kunert R. Nomenclature of humanized mAbs: early concepts, current challenges and future perspectives. Hum Antibodies 2019;27:37-51. https://doi.org/10.3233/HAB-180347
- Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(5 Suppl 14):66-73.
- Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs 2016;8:1177-1194. https://doi.org/10.1080/19420862.2016.1212149
- Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain 2019;20:66. https://doi.org/10.1186/s10194-019-1018-8
- Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov 2020;19:441-442. https://doi.org/10.1038/d41573-020-00078-0
- Mendell JR, Khan N, Sha N, Eliopoulos H, McDonald CM, Goemans N, et al. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J Neuromuscul Dis 2021 Feb 19. [Epub]. DOI:10.3233/JND-200548.
- Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to Exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol 2020;77:982-991. https://doi.org/10.1001/jamaneurol.2020.1264
- Anwar S, Yokota T. Golodirsen for Duchenne muscular dystrophy. Drugs Today (Barc) 2020;56:491-504. https://doi.org/10.1358/dot.2020.56.8.3159186
- Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625-635. https://doi.org/10.1056/NEJMoa1710504
- Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22-31. https://doi.org/10.1056/NEJMoa1716793
- Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11-21. https://doi.org/10.1056/NEJMoa1716153
- Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol 2019;6:601-621. https://doi.org/10.1146/annurev-virology-092818-015530
- Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713-1722. https://doi.org/10.1056/NEJMoa1706198
- Oh KW, Moon C, Kim HY, Oh SI, Park J, Lee JH, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med 2015;4:590-597. https://doi.org/10.5966/sctm.2014-0212
- Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. Pharmacol Res 2021;165:105463. https://doi.org/10.1016/j.phrs.2021.105463
- Campagne O, Yeo KK, Fangusaro J, Stewart CF. Clinical pharmacokinetics and pharmacodynamics of selumetinib. Clin Pharmacokinet 2021;60:283-303. https://doi.org/10.1007/s40262-020-00967-y